162.25

0.15% +0.24

BeiGene Ltd ADR (BGNE)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché BGNE Giù? Forum Previsione

Precedente Chiudi:

$162.01

Aprire:

$162.51

Volume 24 ore:

195.01K

Capitalizzazione di mercato:

$16.96B

Reddito:

$2.46B

Utile/perdita netta:

$-881.71M

Rapporto P/E:

-9.7168

EPS:

-16.6978

Flusso di cassa netto:

$-1.75B

1 W Prestazione:

+5.65%

1M Prestazione:

+6.78%

6M Prestazione:

-11.72%

1 anno Prestazione:

-38.77%

Intervallo 1D:

$159.25

$162.51

Portata 52W:

$126.97

$263.15

BeiGene Ltd ADR Stock (BGNE) Company Profile

Nome

BeiGene Ltd ADR

Settore

Healthcare (1213)

Industria

Biotechnology (699)

Telefono

345-949-4123

Indirizzo

94 Solaris Avenue, Camana Bay, George Town

Dipendente

1,700

Cinguettio

@beigeneusa

Prossima data di guadagno

2024-05-08

Ultimi documenti SEC

BGNE's Discussions on Twitter

BeiGene Ltd ADR Stock (BGNE) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-02-06	Ripresa	JP Morgan	Overweight
2023-09-12	Iniziato	Macquarie	Outperform
2023-08-17	Iniziato	Jefferies	Buy
2023-07-17	Iniziato	Citigroup	Buy
2023-06-30	Downgrade	Bernstein	Outperform → Mkt Perform
2023-01-12	Iniziato	Daiwa Securities	Buy
2022-10-13	Aggiornamento	Guggenheim	Neutral → Buy
2022-10-13	Aggiornamento	SVB Leerink	Mkt Perform → Outperform
2022-08-09	Ripresa	JP Morgan	Overweight
2022-03-17	Downgrade	SVB Leerink	Outperform → Mkt Perform
2022-02-07	Iniziato	Deutsche Bank	Buy
2021-10-12	Iniziato	Bernstein	Outperform
2021-10-06	Aggiornamento	CLSA	Underperform → Buy
2021-03-08	Iniziato	China Renaissance	Buy
2021-03-01	Downgrade	CLSA	Outperform → Underperform
2020-11-09	Downgrade	Ladenburg Thalmann	Buy → Neutral
2020-11-06	Downgrade	Maxim Group	Buy → Hold
2020-11-06	Downgrade	Piper Sandler	Neutral → Underweight
2020-07-10	Downgrade	CLSA	Buy → Outperform
2020-03-13	Aggiornamento	Macquarie	Underperform → Neutral
2020-02-18	Ripresa	Goldman	Buy
2020-01-17	Aggiornamento	CLSA	Outperform → Buy
2020-01-17	Ripresa	Morgan Stanley	Overweight
2019-12-16	Downgrade	Guggenheim	Buy → Neutral
2019-12-16	Downgrade	Piper Jaffray	Overweight → Neutral
2019-11-19	Downgrade	UBS	Buy → Neutral
2019-11-13	Downgrade	CLSA	Buy → Outperform
2019-11-04	Reiterato	Maxim Group	Buy
2019-06-04	Iniziato	Bernstein	Outperform
2019-05-10	Aggiornamento	CLSA	Outperform → Buy
2019-03-15	Iniziato	BofA/Merrill	Buy
2019-01-04	Downgrade	CLSA	Buy → Outperform
2018-11-21	Iniziato	JP Morgan	Overweight
2018-09-25	Iniziato	Leerink Partners	Outperform
2018-05-17	Reiterato	Maxim Group	Buy

Mostra tutto

BeiGene Ltd ADR Borsa (BGNE) Ultime notizie

Evaluating BeiGene: Insights From 6 Financial Analysts

Benzinga

4 Analysts Assess BeiGene: What You Need To Know

Benzinga

Lululemon Issues Weak Outlook, Joins Nike And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Benzinga

Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Benzinga

Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session

Benzinga

Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments

Seeking Alpha

BeiGene Ltd ADR Azioni (BGNE) Dati Finanziari

BeiGene Ltd ADR (BGNE) Reddito 2024

BGNE ha riportato un ricavo (TTM) di $2.46 miliardi per il trimestre terminato il 2023-12-31, un +73.65% salita anno su anno.

BeiGene Ltd ADR (BGNE) Reddito netto 2024

BGNE l'utile netto (TTM) è stato di -$881.71 milioni per il trimestre terminato il 2023-12-31, un +56.00% aumento anno su anno.

BeiGene Ltd ADR (BGNE) Flusso di cassa 2024

BGNE ha registrato un flusso di cassa disponibile (TTM) di -$1.75 miliardi per il trimestre conclusosi con 2023-12-31, un +10.79% aumento anno su anno.

BeiGene Ltd ADR (BGNE) Utile per azione 2024

L'utile per azione (TTM) di BGNE è stato pari a -$8.58 per il trimestre terminato il 2023-12-31, un +55.70% crescita anno su anno.

BeiGene Ltd ADR Azioni (BGNE) insider trading

Commercio interno	Relazione	Data	Transazione	Costo	#Azioni	Valore ($)	#Azioni Totale
OYLER JOHN	Chief Executive Officer	Apr 10 '24	Sale	148.89	26,716	3,977,861	12,084
OYLER JOHN	Chief Executive Officer	Apr 09 '24	Sale	153.94	11,200	1,724,078	38,800
OYLER JOHN	Chief Executive Officer	Mar 13 '24	Sale	177.56	12,332	2,189,648	0
OYLER JOHN	Chief Executive Officer	Mar 12 '24	Sale	164.02	37,668	6,178,369	12,332
Wang Julia Aijun	Chief Financial Officer	Feb 29 '24	Sale	167.08	397	66,331	0
Lee Chan Henry	SVP, General Counsel	Jul 31 '23	Sale	216.26	791	171,059	0
Wang Julia Aijun	Chief Financial Officer	Jul 03 '23	Sale	179.55	472	84,747	0
Wu Xiaobin	President, COO & GM China	Jun 26 '23	Sale	182.37	1,495	272,636	0
Wang Lai	Global Head of R&D	Jun 26 '23	Sale	181.92	1,108	201,567	0
Wang Julia Aijun	Chief Financial Officer	Jun 23 '23	Sale	182.85	840	153,594	0